Glyscend Therapeutics

Glyscend Therapeutics is pioneering a novel, non-invasive approach to treating metabolic diseases by orally administering polymers that form a temporary coating in the duodenum, mimicking the duodenal exclusion mechanism of gastric bypass surgery. The company's lead candidate, GLY-200, is in Phase 2 trials for obesity, with potential applications in type 2 diabetes and NAFLD/NASH. Backed by venture capital and led by a team with deep experience in metabolic drug development, Glyscend aims to offer a safe, effective, and accessible alternative to invasive surgical procedures for a massive global patient population.

Mucus Complexing Polymer (MCP) platform: Orally administered polymers that form a reversible, dynamic barrier coating the duodenum to mimic the physiological effects of duodenal exclusion seen in bariatric surgery.

Glyscend competes in the obesity/T2D space against dominant injectable GLP-1 agonists (e.g., semaglutide, tirzepatide) from Novo Nordisk and Eli Lilly, other oral therapies, and medical device companies with endoscopic duodenal exclusion devices. Its key differentiation is an oral, non-systemic, reversible approach that uniquely mimics surgery.